Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2

Abstract

Aim: a prognosis of clinical-economic efficacy of the fixed combination of insulin glargine and lixisenatide (Soliqua SoloStar®) in comparison with standard therapy with focus on micro- and macrovascular complications of Diabetes Mellitus type 2 (T2DM) in the real practice.Materials and Methods. Model of Burden of T2DM has been created in Microsoft Excel 2010 program. Direct (costs of medicines, treatment of main T2DM complications — myocardial infarction, stroke, etc.) as well as indirect costs (GPD losses, disability related payments, etc.) were calculated. Complications’ rate was took from Federal Diabetes Register. Influence on Burden of T2DM was tested with the additional model which can calculate expenditures with different drugs including Soliqua SoloStar® usage.Results. Direct medical costs with Soliqua SoloStar® usage were less in compare with insulin glargine 100 UI/ml on 23,5 % per year due to decreasing level of severe hypoglycemia and possible protective effect on complications of T2DM (better control). Total expenditures for Soliqua SoloStar® were less on 2,5 % annually, in the same time insulin glargine led to total cost increase by 18,4 % per year. So, difference between expenditures in case of Soliqua SoloStar® were less on appr 21 % vs insulin glargine 100 UI/ml. Budget saving is expected as 6,78 ml RUR per year / 1 000 patients in case of Soliqua SoloStar® usage.Conclusion. Soliqua SoloStar® has economic benefits due to T2DM complications and severe hypoglycemia reduction risks.

Keywords

• сахарный диабет 2-го типа
• инсулин гларгин
• ликсисенатид
• оценка технологии здравоохранения